

Devic's Syndrome (Neuromyelitis Optica) Treatment Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/D2D826CC8A17EN.html>

Date: March 2022

Pages: 64

Price: US\$ 3,250.00 (Single User License)

ID: D2D826CC8A17EN

Abstracts

Devic's syndrome is also known as neuromyelitis optica which is a central nervous system disorder that specifically affects eye nerves and spinal cord.

This report contains market size and forecasts of Devic's Syndrome (Neuromyelitis Optica) Treatment in Global, including the following market information:

Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Devic's Syndrome (Neuromyelitis Optica) Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Eculizumab Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Devic's Syndrome (Neuromyelitis Optica) Treatment include Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidiary of Pfizer), Lupin Ltd., Sagent Pharmaceuticals, Inc., Zydus Pharmaceuticals, Inc., Sandoz Inc. (Novartis) and Alkem Laboratories Ltd., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Devic's Syndrome (Neuromyelitis Optica) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Segment Percentages, by Type, 2021 (%)

Eculizumab

Methylprednisolone

Azathioprine

Mycophenolate Mofetil

Rituximab

Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinic

Others

Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Devic's Syndrome (Neuromyelitis Optica) Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Devic's Syndrome (Neuromyelitis Optica) Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Alexion Pharmaceuticals, Inc.

Teva Pharmaceuticals

Fresenius Kabi AG

Pharmacia & Upjohn (a subsidiary of Pfizer)

Lupin Ltd.

Sagent Pharmaceuticals, Inc.

Zydus Pharmaceuticals, Inc.

Sandoz Inc. (Novartis)

Alkem Laboratories Ltd.

Mylan Pharmaceuticals, Inc.

Hoffmann-La Roche/ Chugai Pharmaceutical

MedImmune LLC

RemeGen, Ltd.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Devic's Syndrome (Neuromyelitis Optica) Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL DEVIC'S SYNDROME (NEUROMYELITIS OPTICA) TREATMENT OVERALL MARKET SIZE

- 2.1 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size: 2021 VS 2028
- 2.2 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Devic's Syndrome (Neuromyelitis Optica) Treatment Players in Global Market
- 3.2 Top Global Devic's Syndrome (Neuromyelitis Optica) Treatment Companies Ranked by Revenue
- 3.3 Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Devic's Syndrome (Neuromyelitis Optica) Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Devic's Syndrome (Neuromyelitis Optica) Treatment Product Type

3.6 Tier 1, Tier 2 and Tier 3 Devic's Syndrome (Neuromyelitis Optica) Treatment Players in Global Market

3.6.1 List of Global Tier 1 Devic's Syndrome (Neuromyelitis Optica) Treatment Companies

3.6.2 List of Global Tier 2 and Tier 3 Devic's Syndrome (Neuromyelitis Optica) Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size Markets, 2021 & 2028

4.1.2 Eculizumab

4.1.3 Methylprednisolone

4.1.4 Azathioprine

4.1.5 Mycophenolate Mofetil

4.1.6 Rituximab

4.2 By Type - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue & Forecasts

4.2.1 By Type - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, 2017-2022

4.2.2 By Type - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, 2023-2028

4.2.3 By Type - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Clinic

5.1.4 Others

5.2 By Application - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue & Forecasts

5.2.1 By Application - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, 2017-2022

5.2.2 By Application - Global Devic's Syndrome (Neuromyelitis Optica) Treatment

Revenue, 2023-2028

5.2.3 By Application - Global Devic's Syndrome (Neuromyelitis Optica) Treatment

Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2021 & 2028

6.2 By Region - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue & Forecasts

6.2.1 By Region - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, 2017-2022

6.2.2 By Region - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, 2023-2028

6.2.3 By Region - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, 2017-2028

6.3.2 US Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.3.3 Canada Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.3.4 Mexico Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, 2017-2028

6.4.2 Germany Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.4.3 France Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.4.4 U.K. Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.4.5 Italy Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.4.6 Russia Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.4.7 Nordic Countries Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.4.8 Benelux Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, 2017-2028

6.5.2 China Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.5.3 Japan Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.5.4 South Korea Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.5.5 Southeast Asia Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.5.6 India Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, 2017-2028

6.6.2 Brazil Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.6.3 Argentina Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, 2017-2028

6.7.2 Turkey Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.7.3 Israel Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.7.4 Saudi Arabia Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

6.7.5 UAE Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Alexion Pharmaceuticals, Inc.

7.1.1 Alexion Pharmaceuticals, Inc. Corporate Summary

7.1.2 Alexion Pharmaceuticals, Inc. Business Overview

- 7.1.3 Alexion Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Major Product Offerings
- 7.1.4 Alexion Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global Market (2017-2022)
- 7.1.5 Alexion Pharmaceuticals, Inc. Key News
- 7.2 Teva Pharmaceuticals
 - 7.2.1 Teva Pharmaceuticals Corporate Summary
 - 7.2.2 Teva Pharmaceuticals Business Overview
 - 7.2.3 Teva Pharmaceuticals Devic's Syndrome (Neuromyelitis Optica) Treatment Major Product Offerings
 - 7.2.4 Teva Pharmaceuticals Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global Market (2017-2022)
 - 7.2.5 Teva Pharmaceuticals Key News
- 7.3 Fresenius Kabi AG
 - 7.3.1 Fresenius Kabi AG Corporate Summary
 - 7.3.2 Fresenius Kabi AG Business Overview
 - 7.3.3 Fresenius Kabi AG Devic's Syndrome (Neuromyelitis Optica) Treatment Major Product Offerings
 - 7.3.4 Fresenius Kabi AG Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global Market (2017-2022)
 - 7.3.5 Fresenius Kabi AG Key News
- 7.4 Pharmacia & Upjohn (a subsidiary of Pfizer)
 - 7.4.1 Pharmacia & Upjohn (a subsidiary of Pfizer) Corporate Summary
 - 7.4.2 Pharmacia & Upjohn (a subsidiary of Pfizer) Business Overview
 - 7.4.3 Pharmacia & Upjohn (a subsidiary of Pfizer) Devic's Syndrome (Neuromyelitis Optica) Treatment Major Product Offerings
 - 7.4.4 Pharmacia & Upjohn (a subsidiary of Pfizer) Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global Market (2017-2022)
 - 7.4.5 Pharmacia & Upjohn (a subsidiary of Pfizer) Key News
- 7.5 Lupin Ltd.
 - 7.5.1 Lupin Ltd. Corporate Summary
 - 7.5.2 Lupin Ltd. Business Overview
 - 7.5.3 Lupin Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Major Product Offerings
 - 7.5.4 Lupin Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global Market (2017-2022)
 - 7.5.5 Lupin Ltd. Key News
- 7.6 Sagent Pharmaceuticals, Inc.
 - 7.6.1 Sagent Pharmaceuticals, Inc. Corporate Summary

- 7.6.2 Sagent Pharmaceuticals, Inc. Business Overview
- 7.6.3 Sagent Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Major Product Offerings
- 7.6.4 Sagent Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global Market (2017-2022)
- 7.6.5 Sagent Pharmaceuticals, Inc. Key News
- 7.7 Zydus Pharmaceuticals, Inc.
 - 7.7.1 Zydus Pharmaceuticals, Inc. Corporate Summary
 - 7.7.2 Zydus Pharmaceuticals, Inc. Business Overview
 - 7.7.3 Zydus Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Major Product Offerings
 - 7.7.4 Zydus Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global Market (2017-2022)
 - 7.7.5 Zydus Pharmaceuticals, Inc. Key News
- 7.8 Sandoz Inc. (Novartis)
 - 7.8.1 Sandoz Inc. (Novartis) Corporate Summary
 - 7.8.2 Sandoz Inc. (Novartis) Business Overview
 - 7.8.3 Sandoz Inc. (Novartis) Devic's Syndrome (Neuromyelitis Optica) Treatment Major Product Offerings
 - 7.8.4 Sandoz Inc. (Novartis) Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global Market (2017-2022)
 - 7.8.5 Sandoz Inc. (Novartis) Key News
- 7.9 Alkem Laboratories Ltd.
 - 7.9.1 Alkem Laboratories Ltd. Corporate Summary
 - 7.9.2 Alkem Laboratories Ltd. Business Overview
 - 7.9.3 Alkem Laboratories Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Major Product Offerings
 - 7.9.4 Alkem Laboratories Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global Market (2017-2022)
 - 7.9.5 Alkem Laboratories Ltd. Key News
- 7.10 Mylan Pharmaceuticals, Inc.
 - 7.10.1 Mylan Pharmaceuticals, Inc. Corporate Summary
 - 7.10.2 Mylan Pharmaceuticals, Inc. Business Overview
 - 7.10.3 Mylan Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Major Product Offerings
 - 7.10.4 Mylan Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global Market (2017-2022)
 - 7.10.5 Mylan Pharmaceuticals, Inc. Key News
- 7.11 Hoffmann-La Roche/ Chugai Pharmaceutical

- 7.11.1 Hoffmann-La Roche/ Chugai Pharmaceutical Corporate Summary
- 7.11.2 Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview
- 7.11.3 Hoffmann-La Roche/ Chugai Pharmaceutical Devic's Syndrome (Neuromyelitis Optica) Treatment Major Product Offerings
- 7.11.4 Hoffmann-La Roche/ Chugai Pharmaceutical Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global Market (2017-2022)
- 7.11.5 Hoffmann-La Roche/ Chugai Pharmaceutical Key News
- 7.12 MedImmune LLC
 - 7.12.1 MedImmune LLC Corporate Summary
 - 7.12.2 MedImmune LLC Business Overview
 - 7.12.3 MedImmune LLC Devic's Syndrome (Neuromyelitis Optica) Treatment Major Product Offerings
 - 7.12.4 MedImmune LLC Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global Market (2017-2022)
 - 7.12.5 MedImmune LLC Key News
- 7.13 RemeGen, Ltd.
 - 7.13.1 RemeGen, Ltd. Corporate Summary
 - 7.13.2 RemeGen, Ltd. Business Overview
 - 7.13.3 RemeGen, Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Major Product Offerings
 - 7.13.4 RemeGen, Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global Market (2017-2022)
 - 7.13.5 RemeGen, Ltd. Key News

8 CONCLUSION

9 APPENDIX

- 9.1 Note
- 9.2 Examples of Clients
- 9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Devic's Syndrome (Neuromyelitis Optica) Treatment Market Opportunities & Trends in Global Market

Table 2. Devic's Syndrome (Neuromyelitis Optica) Treatment Market Drivers in Global Market

Table 3. Devic's Syndrome (Neuromyelitis Optica) Treatment Market Restraints in Global Market

Table 4. Key Players of Devic's Syndrome (Neuromyelitis Optica) Treatment in Global Market

Table 5. Top Devic's Syndrome (Neuromyelitis Optica) Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Devic's Syndrome (Neuromyelitis Optica) Treatment Product Type

Table 9. List of Global Tier 1 Devic's Syndrome (Neuromyelitis Optica) Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Devic's Syndrome (Neuromyelitis Optica) Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Devic's Syndrome (Neuromyelitis Optica) Treatment

Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Devic's Syndrome (Neuromyelitis Optica) Treatment
Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Devic's Syndrome (Neuromyelitis Optica)
Treatment Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Devic's Syndrome (Neuromyelitis Optica)
Treatment Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Devic's Syndrome (Neuromyelitis Optica) Treatment
Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Devic's Syndrome (Neuromyelitis Optica) Treatment
Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Devic's Syndrome (Neuromyelitis Optica) Treatment
Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Devic's Syndrome (Neuromyelitis Optica) Treatment
Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Devic's Syndrome (Neuromyelitis Optica)
Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Devic's Syndrome (Neuromyelitis Optica)
Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Devic's Syndrome (Neuromyelitis Optica)
Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Devic's Syndrome (Neuromyelitis Optica)
Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. Alexion Pharmaceuticals, Inc. Corporate Summary

Table 31. Alexion Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica)
Treatment Product Offerings

Table 32. Alexion Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica)
Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. Teva Pharmaceuticals Corporate Summary

Table 34. Teva Pharmaceuticals Devic's Syndrome (Neuromyelitis Optica) Treatment
Product Offerings

Table 35. Teva Pharmaceuticals Devic's Syndrome (Neuromyelitis Optica) Treatment
Revenue (US\$, Mn), (2017-2022)

Table 36. Fresenius Kabi AG Corporate Summary

Table 37. Fresenius Kabi AG Devic's Syndrome (Neuromyelitis Optica) Treatment
Product Offerings

Table 38. Fresenius Kabi AG Devic's Syndrome (Neuromyelitis Optica) Treatment
Revenue (US\$, Mn), (2017-2022)

Table 39. Pharmacia & Upjohn (a subsidiary of Pfizer) Corporate Summary

Table 40. Pharmacia & Upjohn (a subsidiary of Pfizer) Devic's Syndrome (Neuromyelitis Optica) Treatment Product Offerings

Table 41. Pharmacia & Upjohn (a subsidiary of Pfizer) Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Lupin Ltd. Corporate Summary

Table 43. Lupin Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Product Offerings

Table 44. Lupin Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. Sagent Pharmaceuticals, Inc. Corporate Summary

Table 46. Sagent Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Product Offerings

Table 47. Sagent Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (US\$, Mn), (2017-2022)

Table 48. Zydus Pharmaceuticals, Inc. Corporate Summary

Table 49. Zydus Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Product Offerings

Table 50. Zydus Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (US\$, Mn), (2017-2022)

Table 51. Sandoz Inc. (Novartis) Corporate Summary

Table 52. Sandoz Inc. (Novartis) Devic's Syndrome (Neuromyelitis Optica) Treatment Product Offerings

Table 53. Sandoz Inc. (Novartis) Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (US\$, Mn), (2017-2022)

Table 54. Alkem Laboratories Ltd. Corporate Summary

Table 55. Alkem Laboratories Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Product Offerings

Table 56. Alkem Laboratories Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (US\$, Mn), (2017-2022)

Table 57. Mylan Pharmaceuticals, Inc. Corporate Summary

Table 58. Mylan Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Product Offerings

Table 59. Mylan Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (US\$, Mn), (2017-2022)

Table 60. Hoffmann-La Roche/ Chugai Pharmaceutical Corporate Summary

Table 61. Hoffmann-La Roche/ Chugai Pharmaceutical Devic's Syndrome (Neuromyelitis Optica) Treatment Product Offerings

Table 62. Hoffmann-La Roche/ Chugai Pharmaceutical Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (US\$, Mn), (2017-2022)

Table 63. MedImmune LLC Corporate Summary

Table 64. MedImmune LLC Devic's Syndrome (Neuromyelitis Optica) Treatment Product Offerings

Table 65. MedImmune LLC Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (US\$, Mn), (2017-2022)

Table 66. RemeGen, Ltd. Corporate Summary

Table 67. RemeGen, Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Product Offerings

Table 68. RemeGen, Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Devic's Syndrome (Neuromyelitis Optica) Treatment Segment by Type in 2021

Figure 2. Devic's Syndrome (Neuromyelitis Optica) Treatment Segment by Application in 2021

Figure 3. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue in 2021

Figure 8. By Type - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share, 2017-2028

Figure 9. By Application - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share, 2017-2028

Figure 10. By Region - Global Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share, 2017-2028

Figure 11. By Country - North America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share, 2017-2028

Figure 12. US Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share, 2017-2028

Figure 16. Germany Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 17. France Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share, 2017-2028

Figure 24. China Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 28. India Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. Alexion Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Teva Pharmaceuticals Devic's Syndrome (Neuromyelitis Optica) Treatment

Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Fresenius Kabi AG Devic's Syndrome (Neuromyelitis Optica) Treatment

Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Pharmacia & Upjohn (a subsidiary of Pfizer) Devic's Syndrome

(Neuromyelitis Optica) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Lupin Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Sagent Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Zydus Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Sandoz Inc. (Novartis) Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Alkem Laboratories Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Mylan Pharmaceuticals, Inc. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Hoffmann-La Roche/ Chugai Pharmaceutical Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. MedImmune LLC Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. RemeGen, Ltd. Devic's Syndrome (Neuromyelitis Optica) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Devic's Syndrome (Neuromyelitis Optica) Treatment Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/D2D826CC8A17EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D2D826CC8A17EN.html>